Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Linzess is a prescription guanylate cyclase-C agonist containing linaclotide. Current labeling includes irritable bowel syndrome with constipation in adults and pediatric patients age 7 and older, chronic idiopathic constipation in adults, and functional constipation in pediatric patients age 2 and older. Capsules contain 72 mcg, 145 mcg, or 290 mcg.
read more about linzess ...Linaclotide and its active metabolite bind guanylate cyclase-C receptors on the intestinal surface. This increases cyclic guanosine monophosphate, promotes chloride and bicarbonate secretion into the intestine, increases intestinal fluid, and speeds intestinal transit.
Linzess is used in adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. It is also used from age 7 for irritable bowel syndrome with constipation and from age 2 for functional constipation. Known or suspected mechanical gastrointestinal obstruction is a contraindication.
Adults with irritable bowel syndrome with constipation take 290 mcg once daily. Adults with chronic idiopathic constipation take 145 mcg once daily or 72 mcg once daily according to clinical presentation and tolerability. Patients age 7 and older with irritable bowel syndrome with constipation take 145 mcg once daily, while patients age 2 and older with functional constipation take 72 mcg once daily. Doses are taken on an empty stomach at least 30 minutes before a meal.
Linzess carries a boxed warning for serious dehydration in pediatric patients younger than 2 and is contraindicated in this age group. Severe diarrhea can cause dizziness, fainting, low blood pressure, low potassium, or low sodium and can require intravenous fluids or hospitalization. Severe diarrhea calls for treatment interruption and rehydration.
Current labeling includes irritable bowel syndrome with constipation, adult chronic idiopathic constipation, and pediatric functional constipation under age-specific criteria.
The recommended adult dose is 290 mcg once daily.
Patients age 2 and older with functional constipation receive 72 mcg once daily.
Yes. The boxed warning concerns serious dehydration in pediatric patients younger than 2, and Linzess is contraindicated in this age group.
DailyMed - LINZESS (linaclotide) capsule, gelatin coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09beda19-56d6-4a56-afdc-9a77b70b2ef3. Date Accessed October 13, 2026.
Linaclotide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548021/. Date Accessed October 13, 2026.
Linaclotide. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a613007.html. Date Accessed October 13, 2026.
Linaclotide. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/16158208. Date Accessed October 13, 2026.
LINZESS (linaclotide) Prescribing Information. AbbVie. https://www.rxabbvie.com/content/dam/rxabbvie/pdf/linzess_pi.pdf. Date Accessed October 13, 2026.